Icatibant Zentiva

Icatibant acetate, the active ingredient in Icatibant Zentiva, is a bradykinin B2 receptor antagonist presented as a sterile injection solution for subcutaneous administration. It is indicated for the treatment of acute hereditary angioedema attacks in adult patients, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH USA supplies Icatibant Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide under stringent quality and regulatory standards. The product is sourced from the European Union market, ensuring compliance with EU pharmacopoeial specifications.

Icatibant Zentiva acts on the bradykinin pathway to treat hereditary angioedema attacks.

- Hereditary angioedema type I: rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: alleviates symptoms of sudden edema. - Hereditary angioedema with normal C1‑inhibitor: provides symptom control during attacks.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the subcutaneous injection site. - Injection site erythema: redness around the injection area. - Injection site swelling: localized edema. - Nausea: feeling of stomach upset. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Paradoxical angioedema: worsening swelling despite treatment. - Thrombocytopenia: reduced platelet count. - Injection‑site infection: signs of local infection such as warmth, pus, or fever.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown safety; weigh maternal benefit against potential infant exposure. - Renal impairment: no dose adjustment required, but monitor renal function. - Concomitant ACE inhibitors: may reduce therapeutic effectiveness of icatibant. - Hypersensitivity: discontinue immediately if a severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin system or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may diminish icatibant's efficacy. - Angiotensin receptor blockers: similar potential to reduce therapeutic effect. - C1‑esterase inhibitor concentrates: concurrent use not recommended.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may alter bradykinin levels. - NSAIDs: could increase risk of edema. - Antihistamines: may mask early signs of an allergic reaction.